Skip to content

Ayahuasca: all studies

Page 118 of 167: studies 1,171 to 1,180 of 1,663, newest first. Back to the ayahuasca overview

Research

Psychedelics in Psychiatry: New Treatment Paradigms or Addictive Treatment Strategies? A Narrative Review

Pharmaceutical Science December 9, 2025 Marco Otto Toscano, Serena Chiara Civardi, Federico Durbano

Scientific interest in psychedelics, documented since the nineteenth century, has recently resurged after decades of prohibition. Contemporary research highlights their therapeutic potential in treatment-resistant psychiatric disorders, alongside their heuristic value for studying brain networks and consciousness. This chapter reviews the historical trajectory, traditional uses, mechanisms of...

DOI: 10.5772/intechopen.1014070 (opens in new tab) Enthusiasm Narrative review Perspective graphical Ambivalence +7

N, N-Dimethyltryptamine and harmine formulation shifts metastable topography sequences in the cortex

bioRxiv (Cold Spring Harbor Laboratory) December 9, 2025 Maria Niedernhuber, Dila Suay, Michael J Mueller et al. 1 citation preprint

Abstract Classic serotonergic psychedelics are potent modulators of conscious awareness, yet the principles governing their effects on the temporal dynamics of brain activity remain unclear. Dominant theories propose that psychedelics increase the signal diversity and metastability of neural states, but whether this reflects a simple randomization of activity or a more structured reorganization...

DOI: 10.64898/2025.12.04.692302 (opens in new tab) Ministate Metastability Hallucinating Neocortex +14

Micro-Messiahs: When Psychedelics and Politics Meet

December 2, 2025 Leor Roseman

The recent mainstreaming of psychedelics has distanced itself from the countercultural image of the past, yet the question of whether psychedelics are political remains pressing. What happens when psychedelics meet politics?On one hand lies the politics of the unitive mystical experience: harmony, beyond good & evil, beyond space & time, and with love to all. Studying ayahuasca groups of...

Psychedelics for the Treatment of Substance Use Disorders

SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice December 1, 2025 Johannes Klaus, Fritz Schneider, Rena Schaletzky et al.

Abstract: Background: Psychedelic-assisted therapy is increasingly being explored as potential treatment for substance use disorders (SUDs). While multiple systematic reviews and meta-analyses have examined this topic, the efficacy, method­ological quality, and overlap of the existing evidence base remain unclear. Methods: We conducted an umbrella review of systematic reviews and meta-analyses...

Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community.

Harm Reduction Journal November 25, 2025 Daniel J. Kruger, Gina Mersereau, Ashley Sullivan et al. 1 citation

BACKGROUND: The use of psychedelics is currently increasing in the United States. Awareness of clinical trials investigating the therapeutic applications of psychedelics may result in a record number of people who use psychedelics for the first-time. This study aimed to develop a harm-reduction resource to facilitate safe and successful psychedelic experiences outside of regulated clinical and...

Acute experiences and persisting psychological effects associated with an encapsulated DMT-harmala alkaloid combination: results of a phase 1 study.

Scientific Reports November 20, 2025 Daniel Perkins, Andreas Halman, Anna Urokohara et al.

Acute subjective experiences induced by psychedelics have been identified as important mediators of therapeutic outcomes in many studies. Mystical experiences specifically, have been correlated with a range of therapeutic outcomes including reductions in symptoms of depression, anxiety and addiction. This paper assesses acute subjective experiences induced by an encapsulated DMT-harmala...

DOI: 10.1038/s41598-025-25767-x (opens in new tab) Full text (opens in new tab) Clinical study Harmala Mystical experiences Psychedelics: DMT +20

Psychedelic Augmentation of 12-Step Engagement: A Novel, Accessible Approach to Enhance Community-Based Recovery from Substance Use Disorders.

Journal of Psychoactive Drugs November 10, 2025 Nicky J. Mehtani, Maha N. Mian, Gabrielle Agin-Liebes et al. 1 citation

Amid an evolving psychedelic drug policy landscape and limitations of existing substance use disorder (SUD) treatments, a novel addiction recovery paradigm has emerged involving augmentation of 12-Step program engagement with therapeutic psychedelic use. A preliminary qualitative analysis was initiated to describe this movement by examining real-world experiences of participants in remission...

DOI: 10.1080/02791072.2025.2583960 (opens in new tab) Full text (opens in new tab) Addiction Community-based treatment Substance use disorders 12-step recovery +1

Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.

European Neuropsychopharmacology November 7, 2025 Mikkel Højlund, Helin Y. Kafali, Begüm Kırmızı et al. 12 citations

Serotonergic psychedelics and 3,4-methylendioxtmethamphetamine (MDMA) are promising treatments for mental disorders with a continuously evolving evidence base. We searched Pubmed/Scopus/clinical trial registries up to 08july2025 for double-blind randomized controlled trials (RCTs) testing MDMA or serotonergic psychedelics in patients with mental disorders. Primary outcomes were change in...

DOI: 10.1016/j.euroneuro.2025.09.011 (opens in new tab) Psychedelic therapy MDMA Therapy Psychedelic medicine Entheogenic therapy +12

Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes.

Translational Psychiatry October 31, 2025 Giacomo D’andrea, Stefania Chiappini, Laura Ciavoni et al. 3 citations

BACKGROUND: Over the past ten years, several psychedelic compounds, including tryptamines like lysergic acid diethylamide/LSD, psilocybin, ayahuasca, and dimethyltryptamine/DMT, have been tested in clinical trials for a range of psychiatric conditions, such as anxiety and depression. While these compounds are relatively available for treatment, ketamine and its S(+) enantiomer, esketamine, are...

Bruno Latour’s Beings of Religion

Implicit Religion October 30, 2025 André Van der Braak 1 citation

Latour constructs a plurality of ontologies by distinguishing various modes of existence with their own type of existent. One of these modes of existence is religion, which involves invisible “beings of religion.” Latour criticizes both psychological and (onto)theological interpretations of such beings. He distinguishes between psychogenic beings that constitute the self, and beings of religion...